ATRC
AtriCure Inc
$
37.520
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
38.330
Open
36.400
VWAP
37.14
Vol
527.25K
Mkt Cap
1.86B
Low
35.830
Amount
19.58M
EV/EBITDA(TTM)
--
Total Shares
48.38M
EV
1.76B
EV/OCF(TTM)
48.38
P/S(TTM)
3.45
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
138.57M
+12.09%
-0.120
-14.11%
139.62M
+12.35%
-0.049
-38.15%
131.25M
+13.24%
-0.118
-30.86%
Estimates Revision
The market is revising Upward the revenue expectations for AtriCure, Inc. (ATRC) for FY2025, with the revenue forecasts being adjusted by 1.48% over the past three months. During the same period, the stock price has changed by 17.62%.
Revenue Estimates for FY2025
Revise Upward
+1.48%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-28.73%
In Past 3 Month
Stock Price
Go Up
+17.62%
In Past 3 Month
8 Analyst Rating
Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is 49.75 USD with a low forecast of 38.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 37.520
Low
38.00
Averages
49.75
High
60.00
Current: 37.520
Low
38.00
Averages
49.75
High
60.00
Canaccord
William Plovanic
Buy
maintain
$51 -> $53
2025-07-30
Reason
Canaccord
William Plovanic
Price Target
$51 -> $53
2025-07-30
maintain
Buy
Reason
Canaccord analyst William Plovanic raised the firm's price target on AtriCure to $53 from $51 and keeps a Buy rating on the shares. The firm said they reported a very solid Q2, with strength across the rest of the business more than offsetting further degradation of US EPi-Sense/Hybrid. The target increase reflects comp group multiple expansion and increased expectations.
BTIG
Buy
upgrade
$52 -> $54
2025-07-30
Reason
BTIG
Price Target
$52 -> $54
2025-07-30
upgrade
Buy
Reason
BTIG raised the firm's price target on AtriCure to $54 from $52 and keeps a Buy rating on the shares. The company reported a "wow" quarter, exceeding expectations on the top and bottom as revenue growth accelerated to 16.5%, with results driven by new product launches across the Pain and Appendage Management franchises, the analyst tells investors in a research note.
Citizens Capital Markets
Daniel Stauder
Buy
Reiterates
$60
2025-04-02
Reason
Citizens Capital Markets
Daniel Stauder
Price Target
$60
2025-04-02
Reiterates
Buy
Reason
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$66 → $52
2025-03-28
Reason
Canaccord Genuity
William Plovanic
Price Target
$66 → $52
2025-03-28
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on AtriCure to $52 from $66 and keeps a Buy rating on the shares. The firm updated its model folloing the company's Investor Day that both reiterated its 2025 guidance and provided an aspirational LRP that included three-year objectives as well as targets for 2030.
Needham
Mike Matson
Strong Buy
Reiterates
$51
2025-03-27
Reason
Needham
Mike Matson
Price Target
$51
2025-03-27
Reiterates
Strong Buy
Reason
JP Morgan
Lilia-Celine Lozada
Buy
Maintains
$51 → $46
2025-03-27
Reason
JP Morgan
Lilia-Celine Lozada
Price Target
$51 → $46
2025-03-27
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for AtriCure Inc (ATRC.O) is -109.04, compared to its 5-year average forward P/E of -52.25. For a more detailed relative valuation and DCF analysis to assess AtriCure Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-52.25
Current PE
-109.04
Overvalued PE
-35.97
Undervalued PE
-68.54
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
1178.81
Current EV/EBITDA
31.54
Overvalued EV/EBITDA
8471.21
Undervalued EV/EBITDA
-6113.60
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
6.11
Current PS
3.22
Overvalued PS
9.35
Undervalued PS
2.86
Financials
Annual
Quarterly
FY2025Q2
YoY :
+17.09%
136.14M
Total Revenue
FY2025Q2
YoY :
-13.62%
-6.19M
Operating Profit
FY2025Q2
YoY :
-22.70%
-6.19M
Net Income after Tax
FY2025Q2
YoY :
-23.53%
-0.13
EPS - Diluted
FY2025Q2
YoY :
+179.32%
13.96M
Free Cash Flow
FY2025Q2
YoY :
-0.20%
74.54
Gross Profit Margin - %
FY2025Q2
YoY :
-136.32%
1.66
FCF Margin - %
FY2025Q2
YoY :
-33.96%
-4.55
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
655.6K
USD
5
3-6
Months
83.6K
USD
1
6-9
Months
232.5K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
207.4K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
16.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
655.6K
USD
5
3-6
Months
83.6K
USD
1
6-9
Months
232.5K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ATRC News & Events
Events Timeline
2025-07-29 (ET)
2025-07-29
16:03:16
AtriCure cuts FY25 EPS view to (39c)-(34c) from (55c)-(50c), consensus (51c)
2025-07-29
16:02:01
AtriCure reports Q2 adjusted EPS (2c), consensus (16c)
2025-04-29 (ET)
2025-04-29
16:05:26
AtriCure sees FY25 revenue $517M-$527M, consensus $522.85M
Sign Up For More Events
Sign Up For More Events
News
1.0
08-20NewsfilterAtriCure to Take Part in the 2025 Wells Fargo Healthcare Conference
4.0
07-30BenzingaNeedham Maintains Buy on AtriCure, Raises Price Target to $45
2.0
07-30BenzingaWhy LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Sign Up For More News
People Also Watch
IQ
iQIYI Inc
2.680
USD
+3.08%
LC
LendingClub Corp
17.670
USD
+0.28%
GRFS
Grifols SA
9.700
USD
-0.41%
CASH
Pathward Financial Inc
77.310
USD
+1.28%
DAN
Dana Inc
20.110
USD
-1.61%
CNXN
PC Connection Inc
63.140
USD
+0.62%
SPT
Sprout Social Inc
14.330
USD
+0.63%
HPK
Highpeak Energy Inc
6.740
USD
+0.75%
CABO
Cable One Inc
168.390
USD
-0.47%
LZB
La-Z-Boy Inc
33.820
USD
+0.36%
FAQ
What is AtriCure Inc (ATRC) stock price today?
The current price of ATRC is 37.52 USD — it has increased 2.99 % in the last trading day.
What is AtriCure Inc (ATRC)'s business?
What is the price predicton of ATRC Stock?
What is AtriCure Inc (ATRC)'s revenue for the last quarter?
What is AtriCure Inc (ATRC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for AtriCure Inc (ATRC)'s fundamentals?
How many employees does AtriCure Inc (ATRC). have?
